Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K–mutant advanced or metastatic melanoma

Caroline Robert (1) , Keith Flaherty , Paul Nathan , Peter Hersey , Claus Garbe , Mohammed Milhem , Lev Demidov (2) , Peter Mohr , Jessica C. Hassel , Piotr Rutkowski (3) , Reinhard Dummer , Jochen Utikal (4) , Felix Kiecker (5) , James Larkin , Anthony d'Amelio (6) , Bijoyesh Mookerjee (6) , Dirk Schadendorf

1 CHU Besançon - Department of Dermatology
2 N.N. Blokhin Russian Cancer Research Center
3 MCMCC - Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology
4 DKFZ - German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg]
5 Charité - UniversitätsMedizin = Charité - University Hospital [Berlin]
6 Novartis Pharmaceutical Corporation

Domaines: Sciences du Vivant [q-bio]

Caroline Robert, Keith Flaherty, Paul Nathan, Peter Hersey, Claus Garbe, et al.. Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K–mutant advanced or metastatic melanoma. European Journal of Cancer, 2019, 109, pp.61 - 69. ⟨10.1016/j.ejca.2018.12.015⟩. ⟨hal-03486195⟩